Title
Category
Credits
Event date
Cost
  • Antipsychotics
  • Bipolar Disorder
  • Depression
  • Movement Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Tardive Dyskinesia
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
In brief videos, Drs McEvoy and Nierenberg discuss symptoms of tardive dyskinesia (TD), how to observe patients (whether in person or via telemedicine), and how to educate patients and families about TD.
  • Antipsychotics
  • Bipolar Disorder
  • Depression
  • Diagnostic Tools
  • Schizophrenia/ Schizoaffective Disorders
  • Tardive Dyskinesia
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Experts offer a review of the fundamentals of diagnosing and treating tardive dyskinesia.
  • Psychopharmacology
  • Side Effects
  • Depression
  • Bipolar Disorder
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Join Dr Goldberg as he reviews factors that impact the diagnosis of bipolar disorder and current treatments for bipolar depression in adults.
  • Psychopharmacology
  • Side Effects
  • Child and Adolescent Psychiatry
  • Depression
  • Bipolar Disorder
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
What are the evidence-based pharmacologic treatment approaches for pediatric patients with bipolar depression?
  • Patient/Physician Communication
  • Mood Disorders
  • Child and Adolescent Psychiatry
  • Depression
  • Bipolar Disorder
  • Antipsychotics
  • Antidepressants
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Drs Findling and Goldberg offer expertise on the diagnosis and treatment of bipolar disorder in patients of all ages.
  • Depression
  • Bipolar Disorder
  • Bipolar Depression
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Involving patients in designing their own treatment strategies according to their tolerability criteria can help combat the 90% nonadherence rate in patients being treated for bipolar disorder. Find out from experts about best practices in addressing patient concerns and balancing tolerability with efficacy and adherence in treating patients with bipolar disorder.
  • Depression
  • Bipolar Disorder
  • Bipolar Depression
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Adopting consensus guidelines while applying new evidence on the latest treatment options can often be a matter of balancing risks, benefits, and tolerability when addressing acute episodes in bipolar I disorder. Sit in on the discussion between three experts as they discuss guideline-directed treatment strategies that address manic and mixed episodes in patients with bipolar I disorder, and listen to one patient’s journey to hope and recovery.
  • Depression
  • Bipolar Disorder
  • Bipolar Depression
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Dr Goldberg describes the role of the clinician as that of a travel agent, asking the patient, “Where do you want to go; what do you want it to be like there; how do you want to get there;” etc, then providing the patient with the related evidence-supported information. Learn how to become your patients’ travel agent for their journey through optimizing treatment strategies for type I and type II bipolar disorder.
  • Depression
  • Bipolar Disorder
  • Bipolar Depression
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Treating bipolar I and bipolar II depression is not one-size-fits-all. Learn from field experts about practice guidelines, novel agents, and approaches to developing personalized treatment plans for patients with bipolar depression type I and type II.
  • Depression
  • Bipolar Disorder
  • Bipolar Depression
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
As novel agents join the treatment landscape for bipolar I and bipolar II disorder and new data emerge on existing therapeutics, clinicians need education on the latest evidence of the safety and efficacy profiles of existing and emerging treatments for bipolar I and bipolar II disorder. Join Drs Goldberg, DelBello, and Swartz in examining how to integrate this information into clinical practice and provide efficacious and tolerable treatment for patients with bipolar I and bipolar II disorder.

Pages